Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Reiterated by Mizuho

Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “outperform” rating restated by stock analysts at Mizuho in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $74.00 target price on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 279.29% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Lifesci Capital raised Corbus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $82.00 price target on shares of Corbus Pharmaceuticals in a report on Friday. Wedbush cut their price target on Corbus Pharmaceuticals from $85.00 to $51.00 and set an “outperform” rating for the company in a report on Friday. Oppenheimer raised their price target on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Finally, StockNews.com downgraded Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 10th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $65.86.

Corbus Pharmaceuticals Trading Down 62.3 %

NASDAQ CRBP opened at $19.51 on Friday. The company has a market cap of $208.50 million, a PE ratio of -2.80 and a beta of 2.56. Corbus Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $61.90. The stock has a 50 day moving average of $55.03 and a 200-day moving average of $47.01.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.29. As a group, sell-side analysts predict that Corbus Pharmaceuticals will post -3.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ikarian Capital LLC lifted its holdings in shares of Corbus Pharmaceuticals by 185.5% during the first quarter. Ikarian Capital LLC now owns 559,271 shares of the biopharmaceutical company’s stock worth $21,946,000 after buying an additional 363,372 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Corbus Pharmaceuticals by 143.7% during the first quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock worth $17,158,000 after buying an additional 257,808 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth $13,363,000. Darwin Global Management Ltd. bought a new position in shares of Corbus Pharmaceuticals in the second quarter worth $14,267,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Corbus Pharmaceuticals in the first quarter worth $7,554,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.